AYTU BIOPHARMA, INCAYTU

Market cap

$13.75M

P/E ratio

	Aug 31, 2013	Jun 30, 2015	Jun 30, 2016	Jun 30, 2017	Jun 30, 2018	Jun 30, 2019	Jun 30, 2020	Jun 30, 2021	Jun 30, 2022	Jun 30, 2023
Product revenue, net	5,250	261,782	3	3	4	7	28	66	97	107
Cost of sales	-	-	-	-	-	-	-	-	-	41
Gross profit	-	-	-	-	-	-	-	29	52	67
Selling and marketing	-	-	-	-	-	-	-	30	39	41
General and administrative	341,522	4	-	-	-	-	-	26	31	29
Research and development	-	3	6	959,857	167,595	589,072	2	6	14	4
Impairment of other assets	-	-	-	-	-	-	-	-	-	6
Amortization of intangible assets	-	-	664,707	2	2	2	4	6	4	5
Gain from contingent consideration	-	-	-	-	-	-	-	-	2	1
Total operating expenses	548,532	-	24	23	23	24	49	88	164	84
Loss from operations	-52,414	-7,632,320	-21,704,397	-20,125,236	-19,700,234	-16,846,637	-21,130,546	-59	-112	-17
Other expense, net	-	-	-	-	-	80,779	-	-2	-1	-5
Gain on extinguishment of debt	-	-	-	-	-	-	-315,728	-2	0	-
Gain on derivative warrant liability	-	-	-12,572	212,809	4	-9,830,550	1,830	-	0	5
Total other income, net	-4,904	-	-6,475,687	-2,383,068	10	-10,285,271	8	1	1	0
Loss before income tax	-	-7,747,314	-28,180,084	-	-	-	-	-58	-110	-17
Income tax benefit	-	-23,910	-	-	-	-	-	0	-0	-
Net loss	-57,318	-7,723,404	-28,180,084	-22,508,304	-10,187,863	-27,131,908	-13,620,679	-58	-110	-17
Earnings Per Share, Basic	-	-	-	-	-	-	-	-	-3.39	-5.11
Earnings Per Share, Diluted	-	-	-	-	-	-	-	-	-3.75	-5.11